{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:43Z","timestamp":1792601443930,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04564-7","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:02:04Z","timestamp":1786525324000},"page":"3288-3293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line PD-1\/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Xiying","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-386X","authenticated-orcid":false,"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-5147","authenticated-orcid":false,"given":"Zhongmin Maxwell","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-0842","authenticated-orcid":false,"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-6081","authenticated-orcid":false,"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"4564_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat. Med. 31, 1154\u20131162 (2025).","journal-title":"Nat. Med."},{"key":"4564_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4564_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"4564_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288\u2013300 (2019).","journal-title":"JAMA"},{"key":"4564_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","volume":"161","author":"WD den Brok","year":"2017","unstructured":"den Brok, W. D. et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res. Treat. 161, 549\u2013556 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"4564_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","volume":"96","author":"E Gobbini","year":"2018","unstructured":"Gobbini, E. et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur. J. Cancer 96, 17\u201324 (2018).","journal-title":"Eur. J. Cancer"},{"key":"4564_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04316-2","volume":"12","author":"JY Hsu","year":"2022","unstructured":"Hsu, J. Y., Chang, C. J. & Cheng, J. S. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci. Rep. 12, 729 (2022).","journal-title":"Sci. Rep."},{"key":"4564_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2019.1552255","volume":"28","author":"AS Heimes","year":"2019","unstructured":"Heimes, A. S. & Schmidt, M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin. Investig. Drugs 28, 1\u20135 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"4564_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4564_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"4564_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994\u20131004 (2021).","journal-title":"Ann. Oncol."},{"key":"4564_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4564_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"4564_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang, Z. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat. Med. 30, 249\u2013256 (2024).","journal-title":"Nat. Med."},{"key":"4564_CR15","first-page":"A546","volume":"10","author":"T Zhong","year":"2022","unstructured":"Zhong, T. et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in preclinical studies. J. Immunother. Cancer 10, A546\u2013A547 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4564_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.296","volume":"35","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. A phase Ib\/II study to assess the safety and efficacy of PM8002\/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer [abstract no. 348MO]. Ann. Oncol. 35, S361 (2024).","journal-title":"Ann. Oncol."},{"key":"4564_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi, M. et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer 18, 60 (2019).","journal-title":"Mol. Cancer"},{"key":"4564_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","volume":"171","author":"Y Ozaki","year":"2022","unstructured":"Ozaki, Y. et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (WJOG9917B). Eur. J. Cancer 171, 193\u2013202 (2022).","journal-title":"Eur. J. Cancer"},{"key":"4564_CR19","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","volume":"31","author":"M Gion","year":"2025","unstructured":"Gion, M. et al. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Nat. Med. 31, 2746\u20132754 (2025).","journal-title":"Nat. Med."},{"key":"4564_CR20","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin. Cancer Res. 28, 2807\u20132817 (2022).","journal-title":"Clin. Cancer Res."},{"key":"4564_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang, W. et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 332, 561\u2013570 (2024).","journal-title":"JAMA"},{"key":"4564_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 405, 839\u2013849 (2025).","journal-title":"Lancet"},{"key":"4564_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45160-y","volume":"15","author":"Q Li","year":"2024","unstructured":"Li, Q. et al. The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nat. Commun. 15, 1015 (2024).","journal-title":"Nat. Commun."},{"key":"4564_CR24","first-page":"10","volume":"12","author":"SA Im","year":"2024","unstructured":"Im, S. A. et al. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. npj Breast Cancer 12, 10\u201379 (2024).","journal-title":"npj Breast Cancer"},{"key":"4564_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0999-5","volume":"38","author":"E Reguera-Nu\u00f1ez","year":"2019","unstructured":"Reguera-Nu\u00f1ez, E. et al. Therapeutic impact of nintedanib with paclitaxel and\/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. J. Exp. Clin. Cancer Res. 38, 16 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"4564_CR26","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin. Cancer Res. 26, 1712\u20131724 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4564_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111722","volume":"28","author":"T Zhong","year":"2024","unstructured":"Zhong, T. et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience 28, 111722 (2024).","journal-title":"iScience"},{"key":"4564_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/DDDT.S76135","volume":"9","author":"JH Huang","year":"2015","unstructured":"Huang, J. H. et al. Sample sizes in dosage investigational clinical trials: a systematic evaluation. Drug Des. Devel. Ther. 9, 305\u2013312 (2015).","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04564-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:52Z","timestamp":1789480972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4564"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04564-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Y., Z.M.W., B.L. and Y.X. are employees of Akeso Biopharma. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}